GlassScriptPhysician profile
William R Logan
NPI 1750311395
$6,167.60
in general payments reported to CMS, 2019-2025
31 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2021: $37.13 · 2022: $252 · 2023: $2,844 · 2024: $2,127 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,551 · Travel and Lodging: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,551.27 |
| Travel and Lodging | $1,218.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,814.81 | 2023 | |
| Abbvie INC. | $1,744.95 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $580.01 | 2019-2024 | Qelbree |
| Lilly USA, LLC | $243.98 | 2022-2025 | Emgality, Kisunla, Reyvow |
| Pfizer INC. | $229.40 | 2023-2025 | |
| Biogen, INC. | $168.83 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Teva Pharmaceuticals USA, INC. | $152.90 | 2019-2024 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $120.53 | 2024-2025 | |
| Celgene Corporation | $110.98 | 2024-2025 | Zeposia |
| Ucb, INC. | $101.40 | 2023-2025 | Briviact, Nayzilam |
| Neurelis, INC. | $96.46 | 2023-2025 | Valtoco |
| Lundbeck LLC | $96.33 | 2024 | Vyepti |
| Emd Serono, INC. | $93.76 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $70.04 | 2023-2024 | Epidiolex |
| Genentech USA, INC. | $66.41 | 2022-2024 | Ocrevus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $65.85 | 2024-2025 | Gamunex-C |
| Amgen INC. | $59.21 | 2019-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $57.15 | 2023-2025 | Rytary, Crexont |
| Vanda Pharmaceuticals INC. | $39.99 | 2024 | Ponvory |
| Janssen Pharmaceuticals, INC | $37.13 | 2021 | |
| Sumitomo Pharma America, INC. | $35.92 | 2023 | Aptiom |
| Impel Pharmaceuticals INC. | $35.83 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $29.58 | 2025 | Symbravo |
| Medtronic, INC. | $26.97 | 2023 | Sensight |
| Catalyst Pharmaceuticals, INC. | $21.89 | 2024 | |
| Mdd US Operations, LLC | $21.80 | 2024 | Apokyn |
| Acadia Pharmaceuticals INC | $17.95 | 2024 | Nuplazid |
| Kyowa Kirin, INC. | $13.84 | 2024 | Nourianz |
| E.R. Squibb & Sons, L.L.C. | $13.70 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Logan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.